Physician profile
Scott K Heflick
NPI 1518975762
$5,347.89
in general payments reported to CMS, 2019-2025
44 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $821 · 2020: $696 · 2021: $683 · 2022: $963 · 2023: $1,359 · 2024: $713 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,162 · Education: $23.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,161.55 |
| Education | $23.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $938.00 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $657.51 | 2019-2023 | |
| Pfizer INC. | $651.18 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $461.63 | 2019-2024 | Jardiance, Stiolto Respimat |
| Novo Nordisk INC | $343.86 | 2019-2025 | Ozempic, Rybelsus, Saxenda |
| Glaxosmithkline, LLC. | $302.58 | 2019-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Sanofi-Aventis U.S. LLC | $251.16 | 2021-2022 | |
| Astellas Pharma US INC | $219.71 | 2019-2024 | Veozah |
| Amgen INC. | $182.32 | 2019-2025 | Repatha, Otezla, Otezla |
| Mylan Specialty L.P. | $116.85 | 2020-2023 | Yupelri |
| Supernus Pharmaceuticals, INC. | $113.80 | 2023-2025 | Qelbree, Qelbree |
| Xeris Pharmaceuticals, INC. | $97.68 | 2023-2024 | Gvoke Hypopen, Recorlev |
| Takeda Pharmaceuticals U.S.A., INC. | $90.57 | 2020-2023 | Entyvio |
| Novartis Pharmaceuticals Corporation | $81.08 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $76.66 | 2020-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Heflick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.